**Executive Summary**
The Department of Pharmaceuticals launched the Revised Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS) in March 2024 to facilitate technology upgrades for existing pharmaceutical units to meet Revised Schedule-M and WHO-GMP quality standards. The scheme has a financial outlay of ₹300.10 crore for F.Y. 2024-2025 to 2025-2026. As of January 31, 2026, incentives of ₹18.25 crore have been approved for disbursement to 19 pharmaceutical companies.
**Key Points / Main Content**
* **Revised Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS):**
* Launched in March 2024.
* Aims to facilitate technology upgradation to comply with Revised Schedule-M and WHO-GMP standards.
* Financial outlay: ₹300.10 crore from F.Y. 2024-2025 to 2025-2026.
* **Incentives Under RPTUAS:**
* Pharmaceutical units are eligible for incentives ranging from 10% to 20% of investment, up to a maximum of ₹2.00 crore.
* Incentive percentages are based on average turnover in the last three years:
* ₹1 crore to ₹50 crore: 20%
* ₹50 crore to ₹250 crore: 15%
* ₹250 crore to ₹500 crore: 10%
* **Project Sanctions and Disbursements:**
* Projects sanctioned to 255 pharmaceutical companies, totaling ₹248.20 crore.
* Includes ₹5.92 crore for five units in Tamil Nadu.
* As of 31.1.2026, incentives of ₹18.25 crore approved for disbursement to 19 companies.
* **Financial Assistance Release:**
* Release and utilization of financial assistance require certification from the drug regulatory authority regarding compliance with the revised Schedule M and WHO-GMP.
* **Annexure-I:**
* Lists 255 pharmaceutical companies approved under the RPTUAS, along with their state and year of sanction.
* **Production Linked Incentive (PLI) Schemes:**
* These schemes encourage private sector investment in manufacturing medicines and pharmaceutical drugs.
* **PLI Scheme for Bulk Drugs:**
* Budgetary outlay of ₹6,940 crore.
* Aims to reduce supply disruption risk for critical APIs by providing financial incentives for the sale of 41 identified KSMs/DIs/APIs.
* 48 projects are approved for manufacturing 33 bulk drugs.
* **PLI Scheme for Pharmaceuticals:**
* Budgetary outlay of ₹15,000 crore.
* Aims to enhance manufacturing capabilities, increase investment, and diversify into high-value goods.
* Incentivizes production of biopharmaceuticals, complex generic drugs, patented drugs, etc., and KSMs/DIs/APIs not covered under the Bulk Drugs scheme.
* 55 applicants are approved for manufacturing pharmaceuticals and in-vitro medical devices (IVDs).
**Impact Analysis**
**Pharmaceutical Units**
* **Impact:** Opportunity to upgrade technology and comply with quality standards, potentially increasing efficiency and market competitiveness through financial assistance (ranging from 10%-20% of investment) to comply with Revised Schedule-M and WHO-GMP standards.
* **Action Required:** Assess current technology against required standards, apply for RPTUAS, ensure certification from drug regulatory authority after upgrades, and initiate necessary actions for compliance to be eligible for financial assistance.
**Drug Regulatory Authority**
* **Impact:** Increased responsibility to certify compliance with revised Schedule M and WHO-GMP standards for pharmaceutical units seeking financial assistance.
* **Action Required:** Develop and implement clear certification processes, conduct thorough assessments, and ensure timely certifications for eligible pharmaceutical units.
**Department of Pharmaceuticals**
* **Impact:** Overseeing the implementation, disbursement, and monitoring of the RPTUAS scheme.
* **Action Required:** Effective management of scheme funds, monitoring progress of technology upgrades, and evaluating the overall impact of the scheme on pharmaceutical manufacturing and quality standards.
Key Entities Referenced
Revised Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS): A scheme to facilitate technology upgradation of existing pharmaceutical units to comply with revised quality standards by providing financial incentives.
Department of Pharmaceuticals: The department responsible for implementing the RPTUAS and PLI schemes mentioned in the document.
Production Linked Incentive (PLI) schemes: Schemes implemented by the Department of Pharmaceuticals to encourage private sector investment in the establishment of more pharma companies and manufacture medicines and pharmaceutical drugs.
Schedule-M: A revised quality standard that pharmaceutical units are incentivized to comply with under the RPTUAS.
Tamil Nadu: Indian state where five units received a total of ₹5.92 crore in grant-in-aid under the RPTUAS.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
Revamped RPTUA Scheme
Posted On: 06 FEB 2026 1:45PM by PIB Delhi
Department of Pharmaceuticals launched Revised Pharmaceutical Technology Upgradation Assistance
Scheme (RPTUAS) in March, 2024 with a view to facilitate technology upgradation of existing
pharmaceutical units to comply with Revised Schedule-M and World Health Organization - Good
Manufacturing Practices (WHO-GMP) quality standards. The financial outlay of the scheme is ₹300.10
crore from F.Y. 2024-2025 to 2025-2026.
Under RPTUAS, Pharmaceutical units are eligible to receive incentive ranging from 10% to 20% subject
to a maximum of ₹ 2.00 crore based on their average turnover during the last three years as per the
following categories:
S. No. Turnover Incentive as % of investment
1. ₹ 1 crore to ₹ 50 crore 20%
2. ₹ 50 crore to ₹ 250 crore 15%
3. ₹ 250 crore to ₹ 500 crore 10%
Projects sanctioned so far involve grant-in-aid to 255 pharmaceutical companies for a total amount
of ₹ 248.20 crore, including five units with grant-in-aid for a total amount of ₹ 5.92 crore in the State of
Tamil Nadu. Release and utilisation of financial assistance under the scheme is to be done on receipt of
certification by the drug regulatory authority concerned regarding compliance with the revised Schedule
M to the Drugs Rules, 1945 and the World Health Organization – Good Manufacturing Practices. List of
255 pharmaceutical companies state and year wise approved under the RPTUAS is at Annexure-I.
As on 31.1.2026, out of 255 approved pharmaceutical companies, the Scheme Steering Committee in its
meeting held on 23.12.2025 has approved the disbursement of incentives amount to the tune of ₹ 18.25
crore to 19 pharmaceutical companies.
The Production Linked Incentive (PLI) schemes implemented by the Department of Pharmaceuticals has
encouraged private sector for the establishment of more pharma companies to manufacture medicines and
pharmaceutical drugs. Scheme-wise details are as under:
(i) PLI Scheme for promotion of domestic manufacturing of critical KSMs/DIs/APIs in
India (commonly known as the PLI Scheme for Bulk Drugs): The scheme, which has a total
budgetary outlay of ₹6,940 crore, aims to avoid disruption in supply of critical active
pharmaceutical ingredients (APIs) used to make critical drugs for which there are no
alternatives by reducing supply disruption risk due to excessive dependence on single source.
The scheme provides financial incentives on the sale of 41 identified KSMs/ DIs/ APIsproducts manufactured through greenfield projects set up under the scheme. Under the
scheme, 48 projects are approved for manufacturing of 33 bulk
drugs.
(ii) PLI Scheme for Pharmaceuticals: The scheme, which has a total budgetary outlay of
₹15,000 crore, aims to enhance India’s manufacturing capabilities by increasing investment
and production in the sector and contributing to product diversification to high-value goods in
the pharmaceutical sector. It incentivises production of high-value medicines such as
biopharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry,
auto-immune drugs, anti-cancer drugs, etc. as well as production of KSMs/ DIs/ APIs other
than those notified under the PLI Scheme for Bulk Drugs, thereby contributing to self-
reliance. Under the scheme, 55 applicants are approved for manufacturing of pharmaceuticals
and in-vitro medical devices (IVDs) manufactured through both greenfield and brownfield
projects.
Annexure-I
List of pharmaceutical companies whose projects have been considered and sanctioned under
RPTUAS
Sr. No State / Union Applicant Pharmaceutical company Year of
Territory sanction
1 Andhra Pradesh Dinakara Life Science Pvt. Ltd. 2024
2 Alapati Pharma
3 Inchem Laboratories Pvt. Ltd.
4 Alivira Animal Health Ltd. 2025
5 Aparna Pharmaceuticals Pvt. Ltd.
6 Sionc Pharmaceutical Pvt. Ltd.
7 Rathnam Pharmaceuticals
8 Assam Signova Healthcare Pvt. Ltd. Unit-II 2025
9 Bihar Ornate Labs Pvt. Ltd. 2024
10 Chandigarh Anuja Healthcare Ltd. 2024
11 Saurav Chemicals Ltd.
12 Torque Pharmaceuticals Pvt. Ltd.13 Dadra and Nagar V S International Pvt. Ltd. 2025
Haveli and
Daman and Diu14 Gujarat Navil Laboratories Pvt. Ltd. 2024
15 Bakul Pharma Pvt. Ltd.
16 Denis Chem Lab Ltd.
17 Sangharsh Lifecare Pvt. Ltd.
18 Virdev Intermediates Pvt. Ltd.
19 Bdr Lifesciences Pvt. Ltd.
20 Kentreck Laboratories Pvt. Ltd.
21 Vasa Pharmachem Pvt. Ltd.
22 Neha Life Science Pvt. Ltd.
23 Arnav Research Laboratories
24 Altis Finchem Pvt. Ltd.
25 Swati Chemicals
26 B. Sharda Pharma Pellets Pvt. Ltd.
27 Adrhim Pharmaceuticals LLP
28 Nucare Laboratories India
29 Shiva Healthcare
30 Exotic Pharma
31 Shc Pharmaceuticals
32 Padmavati Chemicals Pvt. Ltd.
33 Yash Medicare Pvt. Ltd.
34 Avik Pharmaceutical Ltd.35 Rajdip Pharmaceuticals 2025
36 Trio Lifescience Pvt. Ltd.
37 Trio Remedies Pvt. Ltd.
38 Maruti Industries
39 Pulse Pharma Manu Co.
40 C P M Enterprise
41 Salus Pharmaceuticals
42 Sanket Healthcare
43 Sahajanand Life Sciences Pvt. Ltd.
44 Exemed Pharmaceuticals
45 Manish Pharma Lab
46 Sg Healthcare Pvt. Ltd.
47 Suchem Laboratories
48 Krozex Remedies Pvt. Ltd.
49 Shelat Brothers
50 Carewin Pharmaceuticals Gujarat Pvt. Ltd.
51 Luxica Pharma Inc.
52 Techno Drugs And Intermediates Pvt. Ltd.
53 Sbf Pharma Pvt. Ltd.
54 Sruzam Labs Pvt. Ltd.
55 Shree Pharma (India)
56 Lexmark Pharmaceuticals Pvt. Ltd.57 Hbc Healthcare Pvt. Ltd.
58 Lex-Mark Healthcare LLP
59 Seejar Pharmaceuticals
60 Parth Laboratories Pvt. Ltd.
61 Adani Pharmachem Pvt. Ltd.
62 Snj Labs Pvt. Ltd.
63 Vm Chemicals
64 Nira Life Sciences Pvt. Ltd.
65 Bdr Pharmaceuticals International Pvt. Ltd.
66 Nebula Healthcare Ltd.
67 Ethicare Pharmaceuticals Pvt. Ltd.
68 Divine Life Care Pvt. Ltd.
69 Dwarkesh Healthcare
70 Sunij Pharma Pvt. Ltd.
71 Modi Antibiotics
72 Sprout Laboratories Pvt. Ltd.
73 Indamed Pharmaceuticals Pvt. Ltd.
74 Sehat Pharma Pvt. Ltd.
75 Intracin Pharmaceuticals Pvt. Ltd.
76 Navin Saxsena Research And Technology Pvt. Ltd.
77 Vadish Pharma Pvt. Ltd.
78 Apex Formulations Pvt. Ltd.79 Omega Pharmaceuticals
80 Bharat Parenterals Ltd.
81 Oneiro Lifecare Pvt. Ltd.
82 Haryana Protech Biosystem Pvt. Ltd. 2024
83 Mcneil And Argus Pharmaceuticals Ltd.
84 Mitra Industries Pvt. Ltd. 2025
85 Astonea Labs Ltd.
86 Sia Pharma Pvt. Ltd.87 Himachal Pradesh M Sea Pharmaceuticals Pvt. Ltd. 2024
88 Three B Healthcare Ltd.
89 Pharma Force Lab
90 Park Pharmaceuticals
91 Ethix Health Care
92 Bennet Pharmaceuticals Ltd.
93 Maxwell Pharma
94 Auraya Healthcare Unit-II
95 Medoz Pharmaceuticals Pvt. Ltd.
96 Unispeed Pharmaceuticals Pvt. Ltd.
97 Sirmour Remedies Pvt. Ltd.
98 Mediforce Healthcare Pvt. Ltd.
99 Goish Remedies Ltd.
100 Alexi Pharmicia Pvt. Ltd.
101 Brit Lifescience
102 Biodeal Pharmaceuticals Ltd.
103 Next Wave India
104 Varav Biogenesis Pvt. Ltd.
105 Gnosis Pharmaceuticals Pvt. Ltd.
106 Higgs Healthcare
107 Unix Biotech
108 Algen Healthcare Ltd.109 Nixi Laboratories Pvt. Ltd.
110 Medicef Pharma
111 Osper Formulation Pvt. Ltd.
112 Brd Medilabs
113 Legen Healthcare114 Caspian Pharmaceuticals 2025
115 Saphnix Life Sciences
116 Healkraft Pharma (India) Pvt. Ltd.
117 Dm Pharma Pvt. Ltd.
118 Athens Life Sciences
119 Purobien Lifesciences
120 Smayan Healthcare Pvt. Ltd.
121 Soft Touch Pharmaceuticals Pvt. Ltd.
122 Magbro Health Care Pvt. Ltd.
123 Brooks Laboratories Ltd.
124 Syskem Pharmocrats
125 Auraya Healthcare
126 Lifecare Neuro Products Ltd.
127 Hanuchem Laboratories Unit III
128 Himsagar Laboratories Ltd.
129 Mmg Healthcare
130 Vellinton Healthcare
131 Nanz Med Science Pharma Pvt. Ltd.
132 Sarv Bio Labs Pvt. Ltd.
133 Medisys Biotech Pvt. Ltd.
134 Grampus Laboratories
135 Legency Remedies Pvt. Ltd.136 Sunlife Pharma Services
137 Pinnacle Life Science Pvt. Ltd.
138 Martin & Brown Bio Sciences Pvt. Ltd.
139 Pacific India
140 Kantil Pharmaceuticals Pvt. Ltd.
141 Ekanthika Pharmaceuticals
142 Ramom Health Care Pvt. Ltd.
143 Vrindaan Global
144 Curetech Skincare
145 Maxtar Bio Genics
146 Jammu & Vowcare Products 2024
Kashmir
147 Protech Biopharma Pvt. Ltd. 2025
148 Karnataka Ce Chem Pharmaceuticals Pvt. Ltd. 2024
149 Nandu Chemical Industries
150 Recipharm Pharmaservices Pvt. Ltd.
151 Kemwell Biopharma Pvt. Ltd. 2025
152 Anglo-French Drugs & Industries Ltd.
153 Nandu Chemicals Pvt. Ltd.
154 M N Chemicals Ltd.
155 Natural Capsules Ltd.
156 Adeep Life Sciences Pvt. Ltd.
157 Vazrachem Specialities158 Kerala Chethana Formulations Pvt. Ltd. 2025
159 Lab induss Ltd.
160 Megasys Biotek Pvt. Ltd.
161 Madhya Pradesh Zenith Drugs Ltd. 2024
162 Schon Pharmaceuticals Ltd.
163 Modern Laboratories 2025
164 Beryl Drugs Ltd.
165 Nandani Medical Laboratories Pvt. Ltd.
166 Hind Pharma
167 Garima Healthcare Pvt. Ltd.
168 Riemann Labs Pvt. Ltd.
169 Cipco Ltd.
170 Arc Pharmaceuticals171 Maharashtra Scitech Specialities Pvt. Ltd. 2024
172 Murli Krishna Pharma Pvt. Ltd.
173 Emil Pharmaceutical Industries Pvt. Ltd.
174 Aqua Fine Injecta Pvt. Ltd.
175 Srikem Laboratories Pvt. Ltd.
176 Sunshine Organics Pvt. Ltd.
177 Aveo Pharmaceuticals Pvt. Ltd.
178 Embio Ltd.
179 Nitika Pharmaceutical Specialities Pvt. Ltd.
180 Hindustan Antibiotics Ltd.
181 Sequent Scientific Ltd.
182 Kores (India) Ltd.
183 Great Pacific Export Pvt. Ltd.184 Anek Prayog Pvt. Ltd. 2025
185 Vav Lipids Pvt. Ltd.
186 Leben Laboratories Pvt. Ltd.
187 Arco Life Science (India) Pvt. Ltd.
188 Oceanic Laboratories Pvt. Ltd.
189 Surajlok Chemicals Pvt. Ltd.
190 Korten Pharmaceuticals Pvt. Ltd.
191 Eisen Pharmaceutical Co Pvt. Ltd.
192 Sydler Remedies Pvt. Ltd.
193 Anant Pharmaceuticals Pvt. Ltd.
194 Unilab Chemicals And Pharmaceuticals Pvt. Ltd.
195 Zen Chemicals Pvt. Ltd.
196 Orex Pharma Pvt. Ltd.
197 U S Pharma (India) Pvt. Ltd.
198 Flamingo Pharmaceuticals Ltd.
199 Laxachem Organics Pvt. Ltd.
200 Sanpras Health Care Pvt. Ltd.
201 M J Biopharm Pvt. Ltd.
202 Bakul Aromatics And Chemicals Pvt. Ltd.
203 Nysa Biomed Pvt. Ltd.
204 Pell Tech Health Care Pvt. Ltd.
205 Asuwaldi Pharmaceuticals206 Odisha M/S Jagannath Chemical And Pharmaceutical Works 2025
Pvt. Ltd.
207 Punjab Velite Pharmaceuticals 2024
208 Systacare Remedies
209 Gag Pharmaceuticals 2025
210 Rajasthan Lark Laboratories India Ltd. 2024
211 D.D. Pharmaceuticals Pvt. Ltd. 2025
212 Kusum Healthcare Pvt. Ltd.
213 Puducherry Life Care Formulations Pvt. Ltd. 2025
214 Linux Life Sciences Pvt. Ltd.
215 Tamil Nadu Saimirra Innopharm Pvt. Ltd. 2024
216 Tychos Therapeutics Pvt. Ltd. 2024
217 Medibest Pharma Pvt. Ltd.
218 Pharm Products Pvt. Ltd.
219 Bafna Pharmaceuticals Ltd. 2025
220 Telangana Sreepathi Pharmaceuticals Ltd. 2024
221 Dano Vaccines & Biologicals Pvt. Ltd.
222 Magnum Chemi Gran Pvt. Ltd.
223 Sanzyme Pvt. Ltd.
224 Maithri Drugs Pvt. Ltd. 2025
225 Rashmi Pharma Pvt. Ltd.
226 Yeluri Formulations Pvt. Ltd.
227 Kekule Pharma Ltd.228 Uttar Pradesh Radicon Laboratories Ltd. 2024
229 Daffodills Pharmaceuticals Ltd.
230 Indo Gulf Pharmaceuticals 2025
231 Uttarakhand Daffohils Laboratories Pvt. Ltd. 2024
232 Pro-Pharma Care Pvt. Ltd.
233 Sarv Pharmaceuticals
234 Talent Healthcare
235 Prochem Pharmaceuticals Pvt. Ltd.
236 Tosc International Pvt. Ltd.
237 Karnani Pharmaceuticals Pvt. Ltd.
238 Evolet Pharmaceuticals Pvt. Ltd.
239 Indian Drug Vision 2025
240 Cotec Health Care Pvt. Ltd.
241 Aagya Biotech Pvt. Ltd.
242 Rusan Pharma Ltd.
243 Tulbros Formulations
244 Suncare Formulations Pvt. Ltd.
245 Verve Human Care Laboratories A Unit Of Venor
Pharma Ltd.
246 Suraksha Pharma Pvt. Ltd.
247 Supermax Drugs And Pharmaceuticals Pvt. Ltd.
248 Sushima Laboratories249 West Bengal Vulcan Laboratories Pvt. Ltd. 2024
250 Mendine Pharmaceuticals Pvt. Ltd.
251 Diamond Drugs Pvt. Ltd.
252 Pharma Impex Laboratories Pvt. Ltd.
253 Gena Pharmaceuticals Ltd.
254 Hygeia Pharmaceuitcals Mfg Pvt. Ltd. 2025
255 Tetradrip Pharma Pvt. Ltd.
This information was given by the Union Minister for Chemicals and Fertilizers, Shri Jagat Prakash
Nadda in a written reply in the Lok Sabha today.
***
PC/PM
(Release ID: 2224373) Visitor Counter : 188
Read this release in: Urdu